|
ワカバヤシ ヒデタカ
Wakabayashi Hidetaka
若林 秀隆 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 総説 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 招待の有無 | 招待あり |
| 表題 | Anamorelin in Japanese patients with cancer cachexia: an update. |
| 掲載誌名 | 正式名：Current opinion in supportive and palliative care 略 称：Curr Opin Support Palliat Care ISSNコード：17514266/17514258 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.1 |
| 著者・共著者 | Wakabayashi Hidetaka, Arai Hidenori, Inui Akio |
| 担当区分 | 筆頭著者,責任著者 |
| 発行年月 | 2023/06 |
| 概要 | PURPOSE OF REVIEW:Anamorelin was approved for production and marketing in Japan on 22 January 2021 for cancer cachexia in non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. The authors describe the updates of anamorelin for cancer cachexia in Japan.RECENT FINDINGS:Recent evidence showed that anamorelin improved lean body mass, body weight, and appetite in patients with cancer cachexia in clinical practice. Anamorelin does not increase body weight in the severe-weight-loss group in cachectic patients with pancreatic cancer. Several case reports showed that anamorelin can cause cardiac adverse drug reactions. Among the cardiac adverse reactions, fatal arrhythmias should be monitored carefully even if it is the first dose. Anamorelin combined with nutrition, physical activity, and exercise may be more useful than anamorelin alone for treating cancer cachexia. An interim analysis from post-marketing all-case surveillance was performed; however, details have not yet been published. When anamorelin cannot be used for cancer cachexia, Kampo medicines can be considered as an option.SUMMARY:Anamorelin has changed the clinical practice of cancer cachexia in Japan. The authors hope that anamorelin is available for other disease-related cachexia along with appropriate multidisciplinary interventions. |
| DOI | 10.1097/SPC.0000000000000658 |
| PMID | 37389636 |